The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study will evaluate the effect of 12 weeks of treatment with tamibarotene compared with placebo on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF).
Epistemonikos ID: 62e9d68bcc6379a4f9e27a176c95b7b779448b2e
First added on: Oct 03, 2026